Korean Journal of Chemical Engineering, Vol.28, No.9, 1918-1923, September, 2011
Establishment of a solvent map for formation of crystalline and amorphous paclitaxel by solvent evaporation process
E-mail:
This study intended to establish a solvent map for formation of crystalline and amorphous paclitaxel by a solvent evaporation process. Crystalline paclitaxel was produced by evaporation with polar solvents (acetone, acetonitrile, ethanol, isobutyl alcohol, methanol, methyl ethyl ketone, and n-butyl alcohol) having a polarity index above 4.00. On the other hand, amorphous paclitaxel was produced by evaporation with non-polar solvents (methylene chloride, n-butyl chloride, and toluene) having a polarity index of about 4.00 or lower. The formation of paclitaxel was very closely associated with the polarity index of the organic solvent used in the solvent evaporation process. In the case of crystalline paclitaxel, the higher the polarity index and the lower the viscosity of the organic solvent (n-butyl alcohol, methyl ethyl ketone, and acetonitrile), the higher the degree of crystallinity. In the case of amorphous paclitaxel, the shape and size of particles varied according to the solvent (methylene chloride, n-butyl chloride, and toluene) used in the solvent evaporation process.
- Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT, J. Am. Chem. Soc., 93, 2325 (1971)
- Schiff PB, Fant J, Horwitz SB, Nature., 277, 665 (1979)
- Rowinsky EK, Cazenave LA, Donehower RC, J. Natl. Cancer Inst., 82, 1247 (1990)
- Han MG, Jeon KY, Mun S, Kim JH, Process Biochem., 45, 1368 (2010)
- Kim JH, J. Biotechnol. Bioeng., 21, 1 (2006)
- Jeon KY, Kim JH, Process Biochem., 44, 736 (2009)
- Hyun JE, Kim JH, J. Biotechnol. Bioeng., 23, 281 (2008)
- Rao KV, Hanuman JB, Alvarez C, Stoy M, Juchum J, Davies RM, Baxley R, Pharm. Res., 12, 1003 (1995)
- Baloglu E, Kingston DG, J. Nat. Prod., 62, 1068 (1999)
- Choi HK, Park YS, Son JS, Hong SS, Song JY, Na GH, J. Plant Biotechnol., 29, 59 (2002)
- Hancock BC, Parks M, Pharm. Res., 17, 397 (2000)
- Hancock BC, Zografi G, J. Pharm. Sci., 86, 1 (1997)
- Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochidian G, Pharm. Res., 12, 945 (1995)
- Karunanithi AT, Acquah C, Achenie LEK, Sithambaram S, Suib SL, Comput. Chem. Eng., 33(5), 1014 (2009)
- Pyo SH, Cho JS, Choi HJ, Han BH, Drying Technol., 25, 1759 (2007)
- Liggins RT, Hunter WL, Burt M, J. Pharm. Sci., 86, 1458 (1997)
- Lee JH, Gi US, Kim JH, Kim Y, Kim SH, Oh H, Min B, Bull. Korean Chem. Soc., 22, 925 (2001)
- Gi US, Min B, Lee JH, Kim JH, Korean J. Chem. Eng., 21(4), 816 (2004)
- Pyo SH, Park HB, Song BK, Han BH, Kim JH, Process Biochem., 39, 1985 (2004)
- Kim WK, Chae HJ, Kim JH, Biotechnol. Bioprocess Eng., 15, 481 (2010)
- Federal Register., ICH guidance Q3C impurities: Residual solvent, 62, 67378 (1997)
- Ferreira V, Fernandez P, Melendez J, Cacho J, J. Chromatogr.A., 695, 41 (1995)
- Chang FH, Lin TC, Chao HR, Chao MR, Int. J. Environ. Anal. Chem., 80, 13 (2001)
- Pyo SH, Kim MS, Cho JS, Song BK, Han BH, Choi HJ, J. Chem. Technol. Biotechnol., 79(10), 1162 (2004)
- Yeo SD, Kim MS, Lee JC, J. Supercrit. Fluids, 25(2), 143 (2003)
- Park HJ, Kim MS, Lee S, Kim JS, Woo JS, Park JS, Hwang SJ, Int. J. Pharm., 328, 152 (2007)
- Sarkar M, Perumal O, Panchagnula R, Indian J. Pharm. Sci., 70, 619 (2008)
- Foks J, Luszczek M, J. Cryst. Growth., 134, 347 (1993)
- Cho EB, Cho WK, Cha KH, Park JS, Int. J. Pharm., 396, 91 (2010)
- Kim BS, Kim JH, Korean J. Chem. Eng., 26(4), 1090 (2009)